Drug Development Pharma - November 19, 2013
Naloxegol reaches milestone
AstraZeneca has announced that the United States Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for naloxegol. The investigational peripherally-acting mu-opioid receptor antagonist (PAMORA) has been studied in opioid-induced constipation (OIC) in adult patients with chronic non-cancer pain, the most common side effect caused by chronic administration of prescription opioid pain […]
Uncategorized - November 18, 2013
Prize to UIC entrepreneurs
The UIC entrepreneur Moa Fransson, researcher at Uppsala University, was the winner of this year’s SEK 100 000 scholarship during the eighth edition of Mentor4Research. During this year’s edition of IVA’s and VINNOVA’s mentor programme 54 researchers from different universities participated. The purpose is to provide researchers with experience and knowledge about commercialisation. Of the […]
Drug Development Pharma - November 18, 2013
Algeta & Bayer granted EU marketing authorization
Algeta and Bayer have received marketing authorisation from the European Commission for Xofigo for the treatment of prostrate cancer patients with bone metastases. According to Oslo Cancer Cluster, the marketing authorization provides approval for the commercialization of Xofigo in all 28 countries of the EU, and in Norway, Iceland and Liechtenstein following national approval. The decision […]
Collaboration - November 8, 2013
Nuevolution in multi-target collaboration deal
The Denmark-based drug discovery company Nuevolution A/S has signed a collaboration deal with Cancer Research Technology to discover anti-cancer drug molecules. The collaboration aims to identify drug leads that block the activity of a number of cancer therapeutic targets. Through the partnership drug candidate molecules which home in on selected targets will be identified by […]
MedTech Business - November 8, 2013
Bactiguard enters five new markets
Swedish medtech company Bactiguard has signed distributor agreements for five new countries. Earlier this year Allmed Group became Bactiguard’s representative in Pakistan. Allmed Group will now be introducing the Bactiguard Infection Protection Program in the three new countries. The company has announced that it is also entering the Polish and Slovenian markets after signing two new distributor […]
Drug Development Pharma - November 8, 2013
EMA seeks information on AstraZeneca’s Brilinta
The European Medicines Agency has contacted AstraZeneca asking the company to provide more information about a U.S. probe into a clinical trial of the company’s new blood thinner Brilinta (ticagrelor), reports Reuters. On November 7 EMA said that it contacted AstraZeneca earlier after the U.S. Department of Justice probe was disclosed by the company on October […]
